TY - JOUR ID - 47118 TI - Concurrent Evaluation of the Expression and Methylation of Secreted Frizzled-Related Protein 2 along with Beta-Catenin Expression in Patients with non-M3 Acute Myeloid Leukemia JO - Iranian Journal of Medical Sciences JA - IJMS LA - en SN - 0253-0716 AU - Mirzaeyan, Fatemeh AU - Chahardouli, Bahram AU - Mirzaeian, Amin AU - Alizad Ghandforoush, Nasrin AU - Alimoghaddam, Kamran AU - Rostami, Shahrbano AD - Department of Hematology and Blood Banking, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran AD - Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran AD - Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran Y1 - 2021 PY - 2021 VL - 46 IS - 3 SP - 180 EP - 188 KW - SFRP2 protein KW - Humans KW - Leukemia KW - Myeloid KW - Acute KW - Beta catenin KW - Wnt signaling pathway DO - 10.30476/ijms.2020.84316.1396 N2 - Background: Wnt signaling is a critical pathway for the development of acute myeloid leukemia (AML). Some studies have evaluated the expression or methylation of secreted frizzled-related protein 2 (SFRP2) as an antagonist and beta-catenin (β-catenin) as a critical mediator of this pathway. Since we found no comprehensive study on these genes in Iran, we aimed to investigate the status of both SFRP2 expression and methylation, and also β-catenin expression, in conjunction with clinical characteristics, in Iranian patients with de novo non-M3 AML.Methods: The methylation and expression of SFRP2 were determined in 188 patients with primary non-M3 AML and 60 healthy controls, who were referred to Shariati Hospital, Tehran, Iran, between January 2017 and February 2019. The methylation-specific polymerase chain reaction (PCR) and real-time quantitative PCR were used, respectively. The expression of β-catenin was explored via real-time quantitative PCR. Statistical analysis was performed using the Mann–Whitney U test (SPSS software, version 23). A P value of less than 0.05 (2-tailed) was considered significant.Results: SFRP2 mRNA showed a significant decline in the AML group compared with the controls (p <0.001). The hypermethylation of the SFRP2 promoter occurred in 25.5% (48/188) of the cases. SFRP2 expression exhibited a negative correlation with the white blood cell count (P=0.003). The expression of β-catenin increased significantly in the patients in comparison with the controls (p <0001), and a significant difference was observed between the patients, who achieved complete remission and those, who did not (P=0.046). Conclusion: The findings of this study showed that alterations in SFRP2 and β-catenin expression can be used as a potential biomarker for differentiating patients with new non-M3 AML from the controls. Additionally, an evaluation of β-catenin expression may be valuable in predicting complete remission in patients with non-M3 AML. UR - https://ijms.sums.ac.ir/article_47118.html L1 - https://ijms.sums.ac.ir/article_47118_08d5f30085c92776f047417b3bffdf46.pdf ER -